<DOC>
	<DOCNO>NCT00003701</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know whether four-drug combination chemotherapy effective two-drug combination chemotherapy treat bladder cancer . PURPOSE : Randomized phase III trial compare effectiveness two combination chemotherapy regimens treat patient bladder cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare recurrence rate overall survival patient treat postoperative adjuvant methotrexate , vinblastine , doxorubicin cisplatin ( M-VAC ) treat combination paclitaxel carboplatin muscle invasive bladder cancer particularly high risk relapse . II . Compare relative toxicity postoperative M-VAC versus encounter postoperative paclitaxel carboplatin . III . Compare quality life score follow completion treatment patient two treatment arm . OUTLINE : This randomize study . Patients stratify N stage ( N0 v N+ ) performance status ( 0-1 v 2 ) . Patients randomize receive methotrexate , vinblastine , doxorubicin , cisplatin ( arm I ) paclitaxel carboplatin ( arm II ) . Arm I : Patients receive methotrexate IV push day 1 , 15 , 22 ; vinblastine IV push day 2 , 15 , 22 ; doxorubicin IV push day 2 ; cisplatin IV 2 hour day 2 . Treatment repeat every 28 day 4 course . Arm II : Patients receive paclitaxel IV 3 hour day 1 follow carboplatin IV 30 minute day 1 . Treatment repeat every 21 day 4 course . Quality life assessment complete pretreatment , prior course 3 , 6 week last dose chemotherapy , 6 , 12 , 24 month end therapy . Patients follow every 3 month year 2 , every 6 month year 2-5 , annually thereafter . PROJECTED ACCRUAL : There 490 patient accrue study within 2.6 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma bladder mixed histology contain component transitional cell carcinoma Must undergone radical cystectomy pelvic lymph node dissection within 12 week prior randomization No evidence distant metastatic disease pre postoperative radiographic scan No positive surgical margin cystectomy specimen know macroscopic residual disease leave time cystectomy No bladder spar surgery May undergone continent urinary diversion neobladder procedure must recover completely effect surgery Must muscleinvasive disease final pathologic stag primary tumor stage pT4 , N , M0 , pT , N+ , M0 , pT3b , N , M , follow pelvic lymph node dissection pathologic nodal stage pN0 ( pT3b pT4 ) , pN1 , pN2 Clinically unsuspected organ confine prostate cancer find cystoprostatectomy allow PATIENT CHARACTERISTICS : Age : Any age Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 2 time ULN Renal : Creatinine great 1.7 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No second degree atrioventricular block bundle branch block Other : No history prior malignancy past 5 year except basal squamous cell carcinoma skin carcinoma situ cervix No active infection require antibiotic No history allergic reaction drug utilize vehicle Cremophor Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Recovered prior therapy Biologic therapy : No prior biologic response modifier therapy No filgrastim ( GCSF ) 24 hour pre postchemotherapy administration Chemotherapy : No prior systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy component bladder spar therapy No prior adjuvant radiotherapy locally advance disease positive margin Surgery : See Disease Characteristics Other : Prior intravesical therapy superficial bladder cancer allow recover</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>stage III bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
</DOC>